Latest On Bone Biologics Corporation (BBLG):
About Bone Biologics Corporation (BBLG):
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
General
- Name Bone Biologics Corporation
- Symbol BBLG
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Devices
- Full Time Employees 1
- Last Split Factor1:10
- Last Split Date2018-07-24
- Fiscal Year EndDecember
- Web URLhttp://www.bonebiologics.com
Financials
- Most Recent Quarter 2019-12-31
- Return on Assets -330%
- Earnings Per Share -$0.62
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 230.12 million
- EBITDA -2702413
- Book Value Per Share -$0.36
Share Statistics
- Shares Outstanding 30.68 million
- Shares Float 26.15 million
- % Held by Insiders 1960%
Technicals
- Beta 0.09
- 52 Week High $7.5
- 52 Week Low $2.5
- 50 Day Moving Average 7.5
- 200 Day Moving Average 5.64
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Bone Biologics Corporation (BBLG) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Bone Biologics Corporation (BBLG) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2019-12-31 | 2019-12-31 | $N/A | -$0.02 | ||
2019-09-30 | 2019-09-30 | $N/A | -$0.08 | ||
2019-06-30 | 2019-06-30 | $N/A | -$0.13 | ||
2019-03-31 | 2019-03-31 | $N/A | -$0.19 | ||
2018-12-31 | 2018-12-31 | $N/A | -$0.06 | ||
2018-09-30 | 2018-09-30 | $N/A | -$0.03 | ||
2018-06-30 | 2018-06-30 | $N/A | -$0.29 | ||
2018-03-31 | 2018-03-31 | $N/A | -$0.33 | ||
2017-12-31 | 2017-12-31 | $N/A | -$0.60 | ||
2017-09-30 | 2017-09-30 | $N/A | -$0.65 | ||
2017-06-30 | 2017-06-30 | $N/A | $0.21 | ||
2017-03-31 | 2017-03-31 | $N/A | -$0.79 | ||
2016-12-31 | 2016-12-31 | $N/A | -$1.26 | ||
2016-09-30 | 2016-09-30 | -$1.13 | |||
2016-06-30 | 2016-06-30 | -$1.26 | |||
2016-03-31 | 2016-03-31 | -$2.01 |
Bone Biologics Corporation (BBLG) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Bone Biologics Corporation (BBLG) Chart:
Bone Biologics Corporation (BBLG) News:
Below you will find a list of latest news for Bone Biologics Corporation (BBLG) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bone Biologics Corporation (BBLG) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Bone Biologics Corporation (BBLG) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-03-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1419554/000149315220004977/0001493152-20-004977-index.htm |
2018-07-25 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000125085318000104/0001250853-18-000104-index.htm |
2018-07-26 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000125085318000106/0001250853-18-000106-index.htm |
2018-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315218010202/0001493152-18-010202-index.htm |
2018-07-23 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315218010351/0001493152-18-010351-index.htm |
2018-07-25 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315218010434/0001493152-18-010434-index.htm |
2018-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315218010971/0001493152-18-010971-index.htm |
2018-08-10 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1419554/000149315218011302/0001493152-18-011302-index.htm |
2018-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1419554/000149315218011715/0001493152-18-011715-index.htm |
2018-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315218013300/0001493152-18-013300-index.htm |
2018-11-14 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1419554/000149315218016147/0001493152-18-016147-index.htm |
2018-11-16 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1419554/000149315218016378/0001493152-18-016378-index.htm |
2019-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003809/0001493152-19-003809-index.htm |
2019-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003931/0001493152-19-003931-index.htm |
2019-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003934/0001493152-19-003934-index.htm |
2019-03-26 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003937/0001493152-19-003937-index.htm |
2019-03-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1419554/000149315219004221/0001493152-19-004221-index.htm |
2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315219005443/0001493152-19-005443-index.htm |
2019-04-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219005760/0001493152-19-005760-index.htm |
2019-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1419554/000149315219006965/0001493152-19-006965-index.htm |
2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219008226/0001493152-19-008226-index.htm |
2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219008227/0001493152-19-008227-index.htm |
2019-05-24 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315219008228/0001493152-19-008228-index.htm |
2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219009559/0001493152-19-009559-index.htm |
2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219009561/0001493152-19-009561-index.htm |
2019-06-21 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315219009562/0001493152-19-009562-index.htm |
2019-06-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315219009880/0001493152-19-009880-index.htm |
2019-07-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315219010722/0001493152-19-010722-index.htm |
2019-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219010724/0001493152-19-010724-index.htm |
2019-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219010727/0001493152-19-010727-index.htm |
2019-08-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219011866/0001493152-19-011866-index.htm |
2019-08-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315219011867/0001493152-19-011867-index.htm |
2019-08-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315219011869/0001493152-19-011869-index.htm |
2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1419554/000149315219012340/0001493152-19-012340-index.htm |
2019-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315219014537/0001493152-19-014537-index.htm |
2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1419554/000149315219017251/0001493152-19-017251-index.htm |
2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1419554/000149315220000387/0001493152-20-000387-index.htm |
2020-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315220000773/0001493152-20-000773-index.htm |
2020-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1419554/000149315220000776/0001493152-20-000776-index.htm |
2020-01-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1419554/000149315220000780/0001493152-20-000780-index.htm |
2020-03-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1419554/000149315220004977/0001493152-20-004977-index.htm |
Bone Biologics Corporation (BBLG) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bone Biologics Corporation (BBLG). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1960%Institutional Ownership: < 1%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2019-07-15 | Bret Hankey | Director | Buy | 85,106.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219010724/0001493152-19-010724-index.htm | ||
2019-06-20 | Don Hankey | Chairman of the Board | Buy | 1,063,830.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219009561/0001493152-19-009561-index.htm | ||
2018-12-17 | Bret Hankey | Director | Buy | 18,009,696.00 | 23,013,754.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003934/0001493152-19-003934-index.htm | ||
2018-12-17 | Don Hankey | Chairman of the Board | Buy | 18,009,696.00 | 24,210,421.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003931/0001493152-19-003931-index.htm | ||
2019-03-25 | Bret Hankey | Director | Buy | 1,489,362.00 | 25,063,903.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003934/0001493152-19-003934-index.htm | ||
2019-03-25 | Don Hankey | Chairman of the Board | Buy | 1,489,362.00 | 25,699,783.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219003931/0001493152-19-003931-index.htm | ||
2019-05-07 | Bret Hankey | Director | Buy | 1,063,830.00 | 26,127,733.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219008226/0001493152-19-008226-index.htm | ||
2019-05-07 | Don Hankey | Chairman of the Board | Buy | 1,063,830.00 | 26,763,613.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219008227/0001493152-19-008227-index.htm | ||
2019-06-20 | Bret Hankey | Director | Buy | 1,063,830.00 | 27,191,563.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219009559/0001493152-19-009559-index.htm | ||
2019-08-06 | Bret Hankey | Director | Buy | 553,191.00 | 27,829,860.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219011867/0001493152-19-011867-index.htm | ||
2019-07-15 | Don Hankey | Chairman of the Board | Buy | 85,106.00 | 27,912,549.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219010727/0001493152-19-010727-index.htm | ||
2020-01-02 | Bret Hankey | Director | Buy | 195,000.00 | 1.00 | 195,000.00 | 28,122,518.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315220000776/0001493152-20-000776-index.htm |
2019-08-06 | Don Hankey | Chairman of the Board | Buy | 553,191.00 | 28,465,740.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315219011866/0001493152-19-011866-index.htm | ||
2020-01-02 | Don Hankey | Chairman of the Board | Buy | 195,000.00 | 1.00 | 195,000.00 | 28,563,398.00 | https://www.sec.gov/Archives/edgar/data/1419554/000149315220000773/0001493152-20-000773-index.htm |